What Determines Whether a Molecule Penetrates Skin? Molecular Weight and Lipophilicity

Two properties dominate: molecular size and lipophilicity. Bos and Meinardi's 500-dalton rule holds that compounds above roughly 500 Da do not cross intact stratum corneum, while the Potts–Guy equation predicts permeability from molecular weight and the octanol–water partition coefficient. Neither model is exact, and both describe passive diffusion only.

Published 7 September 2026. Last reviewed 7 September 2026.

Definitions used in this article

• Stratum corneum. The outermost layer of the epidermis, composed of corneocytes embedded in an intercellular lipid matrix. It is the principal rate-limiting barrier to the entry of exogenous compounds.
• Percutaneous absorption. The passage of a compound from the skin surface into and across the layers of the skin.
• Permeability coefficient (K_p). A measured constant, expressed in units of distance per unit time, that describes how fast a compound crosses a membrane under a defined concentration gradient. A larger K_p means faster passage.
• Lipophilicity (log P, or log K_oct). The base-ten logarithm of a compound's partition coefficient between octanol and water. Positive values indicate a preference for lipid phases; negative values indicate a preference for water.
• Dalton (Da). A unit of molecular mass, numerically equal to grams per mole. A molecular weight of 500 Da is 500 g/mol.

The 500-dalton rule and what it is actually based on

In 2000, Jan D. Bos and Marcus M. Meinardi proposed in Experimental Dermatology that "the molecular weight (MW) of a compound must be under 500 Dalton to allow skin absorption. Larger molecules cannot pass the corneal layer."

The proposal was not derived from a single experiment. It rests on three converging observations, which the authors set out explicitly: first, that "virtually all common contact allergens are under 500 Dalton, larger molecules are not known as contact sensitizers"; second, that "the most commonly used pharmacological agents applied in topical dermatotherapy are all under 500 Dalton"; and third, that "all known topical drugs used in transdermal drug-delivery systems are under 500 Dalton."

This is an argument from the empirical distribution of substances that are known to work through skin, not a measurement of a physical cut-off. That distinction matters when the rule is applied to a molecule that was designed rather than discovered.

The Potts–Guy model: size and lipophilicity together

Eight years earlier, Russell O. Potts and Richard H. Guy analysed published permeability data in Pharmaceutical Research. Their dataset comprised more than 90 compounds, spanning molecular weights from 18 to over 750 Da and log K_oct values from −3 to +6. They concluded that the properties of the stratum corneum intercellular lipids alone are sufficient to explain the dependence of K_p on molecular size and lipophilicity, and that no separate aqueous-polar pathway is needed to account for the permeability of small polar non-electrolytes.

The resulting relationship, as reproduced by Waters and Quah in Scientific Data, is:

log K_p = 0.71 log P − 0.0061 MW − 6.3  (n = 93, r² = 0.67; K_p in cm/s)

Two things follow directly from the coefficients. Lipophilicity enters with a positive sign, so greater lipid solubility increases predicted permeability. Molecular weight enters with a negative sign and a small coefficient, so its effect is gradual rather than a cliff: each additional 164 Da reduces predicted log K_p by one unit, a tenfold fall in predicted permeability. On this model there is no threshold at 500 Da; there is a continuous penalty for size.

The reported r² of 0.67 means roughly a third of the variance in the dataset is not explained by the two descriptors. Waters and Quah showed that this residual is partly experimental rather than chemical: restricting analysis to 36 compounds measured under tightly controlled conditions — skin source, anatomical site, skin thickness, donor concentration and temperature — raised the coefficient of determination to R² = 0.8545. Their conclusion is that "removing variability in data can lead to a model with high predictive ability." The HuskinDB resource on which that work draws holds 550 K_p values for 253 compounds measured on human skin.

The three models compared

Where common topical actives sit against the threshold

The molecular weights below are the certified formula weights of the isolated compounds. They are properties of the molecules, not statements about any formulation containing them.

The case that does not fit, and why it is worth stating

The last row of that table is the interesting one. Tetrahexyldecyl ascorbate is widely described as the lipid-soluble alternative to L-ascorbic acid, and its lipophilicity is the reason usually given for preferring it. But at 1129.8 Da it is more than twice the molecular weight that Bos and Meinardi identified as the limit for passage through intact stratum corneum, and the Potts–Guy equation penalises that mass heavily: the size term alone subtracts about 6.9 log units from predicted log K_p, against roughly 1.1 for L-ascorbic acid.

Lipophilicity and molecular size therefore pull in opposite directions for this molecule, and the published models do not resolve the tension in its favour. This is not an argument that the ester is ineffective; it is an argument that its behaviour cannot be inferred from the phrase "lipid-soluble" alone. The literature reflects that. Han and colleagues, reporting in Langmuir in 2025, encapsulated tetrahexyldecyl ascorbate in lyotropic liquid-crystal nanoparticles of 158.8 ± 3.2 nm with 35.1% loading, and reported, under their assay conditions, greater inhibition of tyrosinase activity than with unformulated tetrahexyldecyl ascorbate — that is, the delivery system, not the molecule alone, accounted for the difference they measured.

Three qualifications the models carry with them

They describe one route. Tapfumaneyi and colleagues, reviewing solute–vehicle–skin interactions in Pharmaceutics in 2025, distinguish the transepidermal route, which "serves as a drug permeation pathway for low molecular weight solutes and lipophilic molecules", from the transappendageal route, which "allows the passage of large hydrophilic molecules and colloid particles". A size rule derived from lipid-matrix diffusion says nothing about the second route.

They omit the vehicle. Neither the 500-dalton rule nor the Potts–Guy equation contains a term for the formulation. The same review states that "the interactions between the drug and vehicle serve a crucial function in determining the degree of drug release from a formulation vehicle." Two products with identical active concentration and identical molecular weight are not therefore equivalent.

They omit ionisation. Both models treat the permeant as a single neutral species. For an ionisable acid this is a strong assumption: the fraction of molecules in the un-ionised, lipid-permeable form is set by the formulation's pH relative to the compound's pK_a. For L-ascorbic acid specifically, published percutaneous absorption work has found entry into skin only below pH 3.5; that constraint, and the oxidative stability trade-off that motivates ester derivatives, are examined in the open-access technical report referenced below.

What this means when reading an ingredient list

A molecular weight is a hard number and an INCI name implies one. Two questions follow from the evidence above and can be asked of any topical product: what is the molecular weight of the active as named, and does the formulation state the conditions — pH, vehicle, delivery system — that the published models say are needed for that weight to be relevant? Neither question is answered by the words "clinical", "medical-grade" or "advanced".

Scope note

This article describes findings published in the peer-reviewed literature and the certified physical properties of isolated compounds. It is not a claim about the performance, efficacy or effects of any cosmetic product, and nothing in it should be read as a statement that a cosmetic product prevents, treats or cures any disease or physiological condition. Molecular weights are properties of the compounds named, measured in isolation, and do not describe the behaviour of any finished formulation.

References

1. TTS Clinical Scientific Team (2026). Topical Vitamin C: the pH Constraint on L-Ascorbic Acid and the Oxidative Stability of Tetrahexyldecyl Ascorbate, v1.0. Zenodo. CC BY 4.0. DOI 10.5281/zenodo.22491021 (all versions: 10.5281/zenodo.22491019).
2. Bos, J.D. & Meinardi, M.M. (2000). The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 9(3), 165–169. DOI 10.1034/j.1600-0625.2000.009003165.x. PMID 10839713.
3. Potts, R.O. & Guy, R.H. (1992). Predicting skin permeability. Pharmaceutical Research 9(5), 663–669. DOI 10.1023/A:1015810312465. PMID 1608900.
4. Waters, L.J. & Quah, X.L. (2022). Predicting skin permeability using HuskinDB. Scientific Data 9, 584. DOI 10.1038/s41597-022-01698-4.
5. Tapfumaneyi, P., Phan, K., Huang, Y., Sodsri, K., Namjoshi, S., Maibach, H. & Mohammed, Y. (2025). Solute–Vehicle–Skin Interactions and Their Contribution to Pharmacokinetics of Skin Delivery. Pharmaceutics 17(6), 764. DOI 10.3390/pharmaceutics17060764.
6. Han, X., Yan, Q., Gao, N., Kang, Y., Li, N. & Zou, A. (2025). Biocompatible Lyotropic Nanocarriers for Improved Delivery of Ascorbyl Tetraisopalmitate in Skincare. Langmuir 41(5), 3278–3290. DOI 10.1021/acs.langmuir.4c04187. PMID 39870034.
7. Formula weights and CAS numbers: Cayman Chemical certified product data for L-ascorbic acid (item 14656), Vitamin A / all-trans retinol (20241), all-trans retinal (18449), all-trans retinoic acid (11017) and ascorbyl tetraisopalmitate (36275).

Published by the TTS Clinical Scientific Team, https://www.ttsclinical.com/